Skip to main content

Table 4 Coincidence of autoantibody subtypes with anti-MCV IgA (AMCV IgA)-positive and -negative patients respecting seropositivity and mean titers at baseline

From: Restrictive IgG antibody response against mutated citrullinated vimentin predicts response to rituximab in patients with rheumatoid arthritis

   AMCV IgA-positive patients AMCV IgA-negative patients Mann–Whitney U P value
(n = 21) (n = 29)
AMCV IgG positive (%, n) 100 % (21/21) 100 % (29/29)  
  negative (%, n) 0 0  
  mean titer (U/ml) 1128.58 548.13 0.012
  SD (U/ml) 1160.25 573.98  
AMCV IgM positive (%, n) 71 % (15/21) 34 % (10/29)  
  negative (%, n) 29 % (6/21) 66 % (19/29)  
  mean titer (U/ml) 98.65 27.1 0.005
  SD (U/ml) 157.69 47.63  
RF IgG positive (%, n) 10 % (2/21) 3 % (1/29)  
  negative (%, n) 90 % (19/21) 97 % (28/29)  
  mean titer (IU/ml) 16.42 9.54 0.013
  SD (IU/ml) 15.62 14.13  
RF IgM positive (%, n) 71 % (15/21) 48 % (14/29)  
  negative (%, n) 29 % (6/21) 52 % (15/29)  
  mean titer (IU/ml) 83.47 34.96 0.071
  SD (IU/ml) 103.29 51.77  
RF IgA positive (%, n) 81 % (17/21) 41 % (12/29)  
  negative (%, n) 19 % (4/21) 59 % (17/29)  
  mean titer (IU/ml) 161.68 88.66 0.003
  SD (IU/ml) 137.91 120.54  
ACCP IgG positive (%, n) 100 % (21/21) 86 % (25/29)  
  negative (%, n) 0 % (0/21) 14 % (4/29)  
  mean titer (U/ml) 1262.77 989.99 0.253
  SD (U/ml) 597.03 776.62  
  1. ACCP, antibodies against cyclic citrullinated peptide; AMCV, antibodies against mutated citrullinated vimentin; n, number of patients; NRRs, non-responders to RTX; RF, rheumatoid factor; RRs, responders to RTX; RTX, rituximab; SD, standard deviation